{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:27:54Z","timestamp":1777930074895,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Sieben Patienten mit hepatisch metastasiertem und progredientem Karzinoid von Ileum oder Caecum wurden mit 2\u20134 \u00d7 106 IE rekombinantem menschlichem Alpha-Interferon (IFN alfa-2b\u00ae, Schering-Plough, Kenilworth, N. J., U.S.A.) subkutan t\u00e4glich oder jeden 2. Tag behandelt. Sechs Patienten hatten Symptome im Sinne eines Karzinoidsyndroms. Bei 6 Patienten blieben Prim\u00e4rtumor und Metastasen zwischen 4 und 40+ Monaten (Median 18) in der Gr\u00f6\u00dfe konstant. Ein Patient zeigte eine hepatische Tumorprogression. Die Ausscheidung von 5-Hydroxyindolessigs\u00e4ure im Urin nahm bei 5 Patienten f\u00fcr 2\u201311 Monate (Median 4) \u00fcber 50% ab. Vier Patienten gaben eine teilweise oder vollst\u00e4ndige R\u00fcckbildung von Flush, Diarrhoe, Obstipation oder Abdominalschmerzen an. Die Nebenwirkungen waren gering und bestanden vornehmlich in Temperaturerh\u00f6hung, Kopfschmerzen und Verwirrtheit w\u00e4hrend der ersten Therapietage. Die Gabe von IFN alfa-2b stellt bei Patienten mit metastasiertem Karzinoid von Ileum oder Caecum und Karzinoidsyndrom eine geeignete palliative Ma\u00dfnahme dar.<\/jats:p>","DOI":"10.1159\/000216440","type":"journal-article","created":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T08:49:09Z","timestamp":1240822149000},"page":"340-344","source":"Crossref","is-referenced-by-count":11,"title":["Zur Behandlung des metastasierten Karzinoids von Ileum und Caecum mit rekombinantem Interferon alpha-2b"],"prefix":"10.1159","author":[{"given":"C.","family":"Doberauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Niederle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Kloke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kurschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.G.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,27]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216440","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000216440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:02:35Z","timestamp":1777680155000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000216440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000216440","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,27]]}}}